Recommendations from the COST action CA17116 (SPRINT) for the standardization of perinatal derivative preparation and in vitro testing

Many preclinical studies have shown that birth-associated tissues, cells and their secreted factors, otherwise known as perinatal derivatives (PnD), possess various biological properties that make them suitable therapeutic candidates for the treatment of numerous pathological conditions. Nevertheles...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Aleksandar Janev, Asmita Banerjee, Adelheid Weidinger, Jure Dimec, Brane Leskošek, Antonietta Rosa Silini, Tina Cirman, Susanne Wolbank, Taja Železnik Ramuta, Urška Dragin Jerman, Assunta Pandolfi, Roberta Di Pietro, Michela Pozzobon, Bernd Giebel, Günther Eissner, Polonca Ferk, Ingrid Lang-Olip, Francesco Alviano, Olga Soritau, Ornella Parolini, Mateja Erdani Kreft
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2023-11-01
Серія:	Frontiers in Bioengineering and Biotechnology
Предмети:	standardization perinatal derivatives recommendations CA17116 (SPRINT) PnD e-questionnaire
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fbioe.2023.1258753/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Recommendations from the COST action CA17116 (SPRINT) for the standardization of perinatal derivative preparation and in vitro testing

Схожі ресурси